The FDA has granted Fremont, Calif.-based Optovue 510(k) clearance for its optical coherence tomography angiography blood vessel measurement technology called Angioanalytics, which facilitates management of progressive blindness-causing diseases. The agency has also cleared the company's 3D projection artifact removal software, which is intended for improving optical coherence tomography angiography image quality.
Optovue's blood vessel measurement tech, 3D PAR software cleared by FDA
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.